Molecular imaging of tucatinib-induced cellular and TME changes in preclinical models of HER2 + breast cancer
Tucatinib significantly decreases intratumoral proliferation and hypoxia in both cell-line and patient-derived xenograft models of HER2 + breast cancer, which can be longitudinally quantified with PET imaging. Our data suggests molecular imaging may improve understanding and prediction of tucatinib response.
Authors
- Patrick N. Song (ORCID: https://orcid.org/0000-0002-1545-0886)
- Anna G. Sorace (ORCID: https://orcid.org/0000-0002-3640-3966)
- Carlos Gallegos (ORCID: https://orcid.org/0000-0002-8336-2677)
- Ameer Mansur (ORCID: https://orcid.org/0009-0005-3750-7141)
- Suzanne E. Lapi (ORCID: https://orcid.org/0000-0003-0090-0191)
- Pragya Ghanate
Institutions
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1007/s10549-026-07936-2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
- National Cancer Institute
- National Institute of General Medical Sciences